Charles River And AAVantgarde Ink CDMO Contract To Produce Good Manufacturing Practice-Plasmid DNA
Critical starting material manufacture for therapeutic targeting high unmet need ophthalmology indication
Charles River Laboratories International, Inc. (NYSE:CRL) and AAVantgarde today announced a contract development and manufacturing organization (CDMO) agreement to produce Good Manufacturing Practice- (GMP) plasmid DNA. AAVantgarde, a clinical-stage biotechnology company with two proprietary adeno-associated viral (AAV) vector platforms for large gene delivery and developing products to treat inherited retinal diseases, will leverage Charles River's expertise in manufacturing GMP plasmid DNA.
AAVantgarde has two proprietary AAV-based large gene delivery platforms, both of which aim to enable efficient delivery of large genes to tissue and cells in vivo. Within this collaboration, Charles River will develop the plasmid DNA for AAVantgarde's Stargardt's disease program (AAVB-039), using their AAV-intein platform, which has demonstrated a very efficient recombination to deliver therapeutically meaningful protein levels.